Table 6.
drug name | disease2 _name |
---|---|
(s)-rolipram | Schizophrenia |
(s)-rolipram | Autistic Disorder |
(s)-rolipram | Bipolar Disorder |
(s)-rolipram | Depression |
ACE INHIBITORS, PLAIN | Angioneurotic Edema |
ACE INHIBITORS, PLAIN | Hypertension |
ACE INHIBITORS, PLAIN | Hypertrophy, Left Ventricular |
ACE INHIBITORS, PLAIN | Coronary Disease |
ACE INHIBITORS, PLAIN | Alzheimer Disease |
ACE INHIBITORS, PLAIN | nondiabetic proteinuric nephropathy |
ACE INHIBITORS, PLAIN | Alcoholism |
ACE INHIBITORS, PLAIN | Abnormalities |
ACE INHIBITORS, PLAIN | Fetal Death |
ACE INHIBITORS, PLAIN | Cardiovascular Abnormalities |
ACE INHIBITORS, PLAIN | Cardiovascular Diseases |
ACE INHIBITORS, PLAIN | Cough |
ACE INHIBITORS, PLAIN | Heart Failure |
ACE INHIBITORS, PLAIN | Kidney Diseases |
ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS | Cardiovascular Diseases |
ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS | Hypertension |
ANTIPSYCHOTICS | Schizophrenia |
BETA BLOCKING AGENTS | Abnormalities |
BETA BLOCKING AGENTS | Fetal Death |
BETA BLOCKING AGENTS | Cardiovascular Abnormalities |
atenolol | glomerulosclerosis |
... | ... |
A selection of existing marketed drugs in TMKB that might potentially be candidates for AD because they are known to modulate genes that are implicated in the disease.